Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Henry Meds vs Longevixx

By GLP-1 ScorecardUpdated

Henry Meds
Site position #47

Higher score

LongevixxFactor scores not reassessed.
Site position #110

Lower score

Score comparison

Henry Meds has the higher recorded score — 77.3/100 to 70.7/100.

Henry Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Henry's low monthly equivalents come with a full year paid upfront, so it is a poor fit for someone shopping for a short trial.

Before you choose

Longevixx does not publish a semaglutide price, so its Longevixx review sets out what it does disclose, while the Henry Meds review explains the conditions attached to Henry Meds's figure. The semaglutide cost page compares published rates across the field. Ask Longevixx for a written total before treating either one as the cheaper choice.

If neither one fits, Henry Meds vs Lumora and Invigor Medical vs Longevixx compare each of them with another graded program, and the list of alternatives to Henry Meds ranks the programs closest to Henry Meds on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

Of the sellers that pay us a commission, the HealthRX review covers one graded close to these two, at 77.5/100. That relationship never changes a grade, and the review lists what we could not verify.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueHenry Meds +18
72
54
Dose & formulationHenry Meds +5
80
75
Clinical oversightHenry Meds +6
80
74
Labs & monitoringLongevixx +6
78
84
FulfillmentLongevixx +1
78
79
Contract termsHenry Meds +11
78
67
Henry Meds · top barLongevixx · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricHenry MedsLongevixx
WeighScore77.3/10070.7/100
GradeC+C
Site position#47#110
Semaglutide$197/mo (injectable; 12-month plan paid upfront in full, $2,364)Current drug-specific price unconfirmed
TirzepatideOral compounded plans; confirm selected price and supplyCurrent drug-specific price unconfirmed
CoverageMulti-stateConfirm availability for the selected treatment and state
Brand-name accessNot confirmedNot confirmed
Oral / sublingualYesNot confirmed
Henry Meds

Site position #47 · C+

Strengths

  • Published plan prices identify their upfront-payment requirement
  • Medication, provider access, applicable supplies and shipping included if prescribed
  • Compounded injectable semaglutide and oral options listed

What to consider

  • The $197 semaglutide headline requires $2,364 upfront, not monthly payments
  • Oral program headings and supply descriptions conflict; obtain the selected written quote
  • Multi-month balances may remain payable after cancellation; medical-discontinuation refunds require documentation and approval, and dispensed medication is excluded
Longevixx

Site position #110 · C

Factor scores not reassessed.

Strengths

  • Publishes separate treatment pages and written recurring-order terms

What to consider

  • The general starting price is not a drug-specific quote
  • Treatment pages and terms give different cancellation notice periods

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard